97066 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans Blood coagulation or fibrinolysis factors
Method for purifying GLA-domain coagulation proteins
#302Antidotes for factor Xa inhibitors and methods of using the same
#303NEW STABILIZING AGENT FOR PHARMACEUTICAL PROTEINS
#304Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof
#305Plasminogen receptor, polypeptides and antibodies thereof
#306Purification of blood coagulation factors
#307Reliable stabilization of N-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns
#308Method for the Preparation of Recombinant Human Thrombin and Fibrinogen
#309BLADDER CANCER BIOMARKER AND TEST METHOD USING THE SAME
#310THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES
#311Conjugated proteins
#312Methods of increasing the expression yield of vitamin K-dependent proteins
#313Factor VII Fusion Polypeptides
#314STABLE SOLUTION
#315Isolated nucleic acids encoding activated factor V and methods for production thereof
#316METHOD OF PRODUCING RECOMBINANT VITAMIN K DEPENDENT PROTEINS
#317Method for purifying active GLA-domain coagulation proteins
#318FACTOR VIII POLYMER CONJUGATES
#319ISOLATED STROMAL CELLS AND METHODS OF USING THE SAME
#320Long-acting coagulation factors and methods of producing same
#321Methods and kits for measuring von willebrand factor
#322Genipin cross-linked fibrin gels
#323TARGETING TISSUE FACTOR TO ACTIVATED PLATELETS
#324Cofactors for Thrombin Activation of Factor VII and Uses Thereof
#325Factor VII or VIIa - Like Molecules
#326Host cell protein knock-out cells for production of therapeutic proteins
#327ALBUMIN FUSED COAGULATION FACTORS FOR NON-INTRAVENOUS ADMINISTRATION IN THE THERAPY AND PROPHYLACTIC TREATMENT OF BLEEDING DISORDERS
#328Pancreatic cancer targets and uses thereof
#329Affinity substrate and methods for selectively purifying a blood plasma protein
#330Signature Of Secreted Protein Isoforms Specific To Ovarian Cancer
#331Virus filtration of liquid factor VII compositions
#332Peptides for binding fibrinogen and fibrin
#333Mutated antithrombins, a process for preparing the same and their use as drugs
#334Modified vitamin K-dependent polypeptides
#335Transgenic non-human animals expressing human blood clotting factors and uses thereof
#336NUCLEIC ACIDS SPECIFICALLY BINDING WITH HUMAN FACTOR VII/VIIA AND USES THEREOF
#337MEANS FOR PURIFYING A COAGULATION PROTEIN, AND METHODS FOR IMPLEMENTING SAME
#338Peptide-based compounds
#339Methods and kits for measuring von Willebrand factor
#340Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
#341Snake factor V and methods of use thereof as a procoagulant
#342ISOLATED PEPTIDES OF RABBIT FACTOR VII
#343Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use
#344PURIFICATION OF FACTOR V
#345Factor VIII polymer conjugates
#346BLADDER CANCER BIOMARKER AND TEST METHOD USING THE SAME
#347PROTEOLYTICALLY CLEAVABLE FUSION PROTEINS WITH HIGH MOLAR SPECIFIC ACTIVITY
#348Immunoglobulin chimeric monomer-dimer hybrids
#349Clotting factor-fc chimeric proteins to treat hemophilia
#350Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin
#351Methods for Chemically Synthesizing Immunoglobulin Chimeric Proteins
#352Modified Blood Clotting Factors And Methods Of Use
#353Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
#354Factor VIII polymer conjugates
#355Factor VIII polymer conjugates
#356Factor VIII polymer conjugates
#357Factor VIII polymer conjugates
#358Factor VIII polymer conjugates
#359Methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
#360Hydrophobic interaction chromatography purification of factor VII polypeptides
#361Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders
#362Covalent Factor VII-Tissue Factor Complex
#363Modified vitamin K-dependent polypeptides
#364Modified vitamin K-dependent polypeptides
#365Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
#366Long-acting coagulation factors and methods of producing same
#367Plasminogen receptor PLG-RKT and antibodies thereof
#368Modified vitamin K-dependent polypeptides
#369Use of mutated antithrombins for treating or preventing coagulation disorders
#370Crystal structure of CRIg and C3b:CRIg complex
#371EXOSITE-DIRECTED THROMBIN INHIBITORS
#372Extended recombinant polypeptides and compositions comprising same
#373Method to produce fibrin monomer in acid media for use as tissue sealant
#374Coagulation factor VII polypeptides
#375Radiofluorination methods
#376Factor VIII polymer conjugates
#377Factor VIII polymer conjugates
#378Pegylated factor VIII
#379Modified factor VII polypeptides and uses thereof
#380Recombinant protein S composition
#381METHOD FOR THE PREPARATION OF RECOMBINANT HUMAN THROMBIN AND FIBRINOGEN
#382Host cell protein knock-out cells for production of therapeutic proteins
#383Modified coagulation factors with prolonged in vivo half-life
#384GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA
#385Factor VIII polymer conjugates
#386Factor VIII polymer conjugates
#387RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHODS OF PREPARING SAME
#388Methods for preparation of platelet rich plasma
#389PURIFICATION OF FACTOR XI
#390METHOD FOR THE EXTRACTION OF ONE OR SEVERAL PROTEINS IN MILK
#391Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
#392Chelator conjugates
#393ISOLATED STROMAL CELLS AND METHODS OF USING THE SAME
#394Methods for treating a hemostasis related disorder using activated forms of Factor V
#395GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA
#396Method for extracting a protein from milk
#397Modified vitamin K-dependent polypeptides
#398Modified vitamin K-dependent polypeptides
#399MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES
#400MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES
#401Focused libraries, functional profiling, laser SELEX, and DESELEX
#402Production of high levels of transgenic factor IX without gene rescue, and its therapeutic uses
#403RECOMBINANT OR TRANSGENIC FACTOR VII COMPOUND HAVING A MAJORITY OF GLYCAN, BIANTENNARY, BISIALYLATED AND NON-FUCOSYLATED FORMS
#404Transgenic Non-Human Animals Expressing Human Blood Clotting Factors and Uses Thereof
#405ISOLATED STROMAL CELLS FOR USE IN THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
#406Peptide-based compounds
#407COAGULATION FACTOR III POLYMORPHISMS ASSOCIATED WITH PREDICTION OF SUBJECT OUTCOME AND RESPONSE TO THERAPY
#408Methods and kits for measuring von Willebrand factor
#409Pancreatic cancer targets and uses thereof
#410Method of Removing a Non-Metallic Protein Inhibitor From a Liquid Pharmaceutical Preparation
#411Modified factor VII polypeptides and uses thereof
#412Kit for protein S functional assay
#413Factor VIII polymer conjugates
#414Proteolytically cleavable fusion proteins with high molar specific activity
#415ISOLATED STROMAL CELLS AND METHODS OF USING THE SAME
#416Factor VII or VIIa—like molecules
#417Enhanced production of blood clotting factors and fibrin fabric
#418O-Linked Glycoforms Of Polypeptides And Method To Manufacture Them
#419Host cell protein knock-out cells for production of therapeutic proteins
#420Purification of recombinant human factor XIII
#421Chimeric proteins with phosphatidylserine binding domains
#422Virus Filtration of Liquid Factor VII Compositions
#423Ligands and libraries of ligands
#424Proteolytically cleavable fusion proteins with high molar specific activity
#425Methods for chemically synthesizing immunoglobulin chimeric proteins
#426Reagent for measuring clotting time and method for stabilizing tissue factor
#427Selective αvβ3 receptor peptide antagonist for therapeutic and diagnostic applications
#428Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest
#429Method for the purification of recombinant blood coagulation factor IX enriched in sulfated and/or phosphorylated molecules
#430MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES
#431Closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit
#432Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
#433Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
#434Methods of treatment involving the protease for activating clotting factor VII
#435Methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
#436Reagent for measuring clotting time and method for manufacturing the reagent
#437Methods of screening for inhibitors of antiplasmin cleaving enzyme
#438Crystal structure of CRIg and C3b:CRIg complex
#439Compositions and methods of preparation thereof
#440Modified vitamin K-dependent polypeptides
#441Human coagulation factor VII polypeptides
#442Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody
#443Modified vitamin K-dependent polypeptides
#444Production of a von Willebrand factor preparation using hydroxylapatite
#445Exosite-Directed Thrombin Inhibitors
#446Stabilized proteins with engineered disulfide bonds
#447Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing
#448Pegylated factor VIII
#449Factor VII or VIIA-like molecules
#450Modified vitamin K-dependent polypeptides
#451Modified vitamin K-dependent polypeptides
#452NATURAL KILLER CELL COMPOSITIONS AND METHOD FOR PRODUCTION OF THE SAME
#453Assays for Determining Anticoagulant Cofactor Activity
#454Mutants of the factor VII epidermal growth factor domain
#455Hydrogels for protein concentration
#456Immunoglobulin chimeric monomer-dimer hybrids
#457Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use
#458RECOMBINANT PLATELET COLLAGEN RECEPTOR GLYCOPROTEIN VI AND ITS PHARMACEUTICAL USE
#459Modified vitamin K. dependent polypeptides
#460Virus filtration of liquid Factor VII compositions
#461Factor VII or VIIa-like molecules
#462Fusion proteins and methods of cleavage of such proteins
#463Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
#464Modified vitamin K-dependent polypeptides
#465Transgenic mouse expressing a polynucleotide encoding human tissue factor
#466Fusion polypeptides, and use thereof in antivascular tumor therapy
#467Modified vitamin K-dependent polypeptides
#468Modified vitamin K-dependent polypeptides
#469Factor VII or VIIa-like molecules
#470Chimeric proteins with phosphatidylserine binding domains
#471Factor VII or VIIa-like molecules
#472Factor VII or VIIa - Like Molecules
#473Factor VII or VIIA-like molecules
#474Factor VII or VIIa - like molecules
#475Factor VII or VIIa-like molecules
#476Mutants of the factor VII epidermal growth factor domain
#477Factor VII or VIIA-like molecules
#478Coagulation Factor VII polypeptides
#479Blood factor domains
#480Thromboplastin reagents
#481Factor VII or VIIa-like molecules
#482Crystal structure of factor Vai and method for identifying blood factor Va modulators
#483Peptide and peptide mimetic derivatives having integrin inhibitor properties III
#484Immunoglobulin chimeric monomer-dimer hybrids
#485Thrombin-cleavable chimeric proteins
#486Protease for activating clotting factor VII
#487Enhanced production of blood clotting factors and fibrin fabric
#488Clotting factor-Fc chimeric proteins to treat hemophilia
#489Protein S functional assay
#490Polynucleotides encoding immunoadhesins comprising a glycoprotein VI domain
#491Modified vitamin K-dependent polypeptides
#492Peptide-based compounds
#493Protein C variants
#494Protein derived from and process preparing the same
#495Immunoglobulin chimeric monomer-dimer hybrids
#496Methods for chemically synthesizing immunoglobulin chimeric proteins
#497Lyophilized fibrin sealant for high volume hemorrhage